Tag Archives: angiotensin-converting enzyme (ACE) inhibitors

Introduction Myocardial fibrosis plays a pivotal role in cardiac pathological processes and the development of complications. Preclinical studies demonstrate that angiotensin-converting enzyme inhibitors (ACEi) have inhibitory effects on fibrotic pathways and could reduce myocardial fibrosis.1 Myocardial fibrosis, triggered by various stimuli, increases morbidity and mortality.2 Azevedo et al. revealed that higher degrees of myocardial fibrosis were associated with worse long-term survival.3 Accumulation of myocardial fibrosis is associated with stiffening of the myocardium and failure to relax during diastole.4 Further, a higher degree of my

ACEi/ARB use Despite overwhelming evidence and innumerable local, regional, national and international guidelines, the prescription of ACEi/ARB therapies for patients with CKD have remained (to use Dr Hostetter’s word) ‘woeful’. North American data showed that between 1999 and 2014 the use of ACEi/ARB therapy in patients with CKD rose from 25.5% between 1999 and 2002 to 40.1% between 2011 and 2014, with their use being the exception unless patients had additional diseases, such as diabetes mellitus or cardiac disease.6 These findings are consistent with National Health and Nutrition Examination Survey data, which suggested that only 39

Background Heart failure is a common cause of hospital admission in the UK, and the leading cause of admission in people aged 65 years or older.1 Treatment with angiotensin-converting enzyme (ACE) inhibitors (ACEi), angiotensin-receptor blockers (ARB) and beta blockers are associated with reduced morbidity and mortality, while prompt imaging with a transthoracic echocardiogram (TTE) enables earlier diagnosis and appropriate management.2 It has been recommended that a TTE should be done within 48 hours of admission. Coronavirus disease 2019 (COVID-19) was declared as a global pandemic on 11 March 2020,3 and the UK had 491,805 cases by 30 Septe

No content available